EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

The Keynote‐177 Randomized Controlled Trial of First‐line PD ‐1 Blockade for Microsatellite‐High or Mismatch Repair‐Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross‐Over Trial Design and Related Issues

S L Gerritse iD, E van Meerten iD, A J Duits iD, J B Schnog iD

Cancer Medicine · 2026-04 · 15 (4)

DOI: 10.1002/cam4.71817 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 14.04.2026. Verfasst von S L Gerritse und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Renier de Graaf Gasthuis, Delft, the Netherlands. Hauptthemen laut MEDLINE: Colorectal Neoplasms, DNA Mismatch Repair, Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Some new oncology drugs offer substantial patient health benefit. However, due to high costs, many remain unavailable to patients in low‐ and middle‐income countries. Next to exorbitant drug pricing, uncertainty of the magnitude of benefit of new treatments can contribute to differences in global access to cancer treatments, even in high‐income countries. Health technology assessment (HTA) organizations employ predetermined criteria to assess whether a drug's efficacy suffices for local approval, ideally informed by randomized controlled trials (RCTs) that provide data on the clinically relevant endpoints overall survival (OS) and quality of life (QoL). Contemporary oncology RCTs increasingly suffer from design and interpretation issues that lead to inadequate data for HTA assessments. The Keynote‐177 RCT was the landmark study demonstrating the superiority of pembrolizumab over chemotherapy in terms of progression free survival and subsequently OS, as a first‐line treatment for patients with metastatic microsatellite instable high (MSI) colorectal cancer (CRC). However, in a trial testing the initial efficacy of immunotherapy in advanced MSI CRC, the allowance of crossover delayed the OS signal. Along with other design‐related limitations, this complicates the precise determination of the absolute benefit of first‐line immunotherapy on OS or quality of life in advanced MSI CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsDNA Mismatch RepairAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorHumansMicrosatellite InstabilityRandomized Controlled Trials as TopicCross-Over StudiesQuality of LifeResearch Design

Stichwörter der Autor:innen

HTAcross‐overglobal accessrandomized controlled trialssubsequent anti‐cancer therapyunbalanced censoring

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorpembrolizumabPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Renier de Graaf Gasthuis, Delft, the Netherlands.
  • Department of Clinical Pharmacology, Renier de Graaf Gasthuis, Delft, the Netherlands.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Curaçao Biomedical & Health Research Institute, Willemstad, Curaçao.
  • Department of Medical Education, Curaçao Medical Center, J.H.J. Hamelbergweg, Willemstad, Curaçao.
  • Institute for Medical Education, University Medical Center Groningen, Hanzeplein 1, the Netherlands.

ORCID-Profile: S L Gerritse, E van Meerten, A J Duits, J B Schnog

Zitieren

APA

Gerritse, S. L., van Meerten, E., Duits, A. J., & Schnog, J. B. (2026). The Keynote‐177 Randomized Controlled Trial of First‐line PD ‐1 Blockade for Microsatellite‐High or Mismatch Repair‐Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross‐Over Trial Design and Related Issues. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71817

Vancouver

Gerritse SL, van Meerten E, Duits AJ, Schnog JB. The Keynote‐177 Randomized Controlled Trial of First‐line PD ‐1 Blockade for Microsatellite‐High or Mismatch Repair‐Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross‐Over Trial Design and Related Issues. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71817

BibTeX
@article{Gerritse2026,
  author = {Gerritse, S L and van Meerten, E and Duits, A J and Schnog, J B},
  title = {The Keynote‐177 Randomized Controlled Trial of First‐line PD ‐1 Blockade for Microsatellite‐High or Mismatch Repair‐Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross‐Over Trial Design and Related Issues},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/cam4.71817}
}
Kostenlos starten →